Trials / Completed
CompletedNCT05392179
A Study in Subjects With Retinitis Pigmentosa
An Open-label, Phase II Study of ADX-2191 in Subjects With Retinitis Pigmentosa
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Aldeyra Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of ADX-2191 in the worse seeing eye. Ocular structure and function will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADX-2191 | Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of three injections. Evaluation through week 16. |
| DRUG | ADX-2191 | Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of six injections. Evaluation through week 16. |
Timeline
- Start date
- 2022-07-14
- Primary completion
- 2023-06-23
- Completion
- 2023-06-23
- First posted
- 2022-05-26
- Last updated
- 2024-04-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05392179. Inclusion in this directory is not an endorsement.